(Q37375243)

20 August 2017

1 reference

title

Delayed onset CMV disease in solid organ transplant recipients (English)

1 reference

20 August 2017

3

Adriana Zeevi

1 reference

20 August 2017

Shahid Husain

1

1 reference

20 August 2017

Carolynn E Pietrangeli

series ordinal

2

1 reference

20 August 2017

publication date

20 January 2009

1 reference

20 August 2017

published in

Transplant Immunology

1 reference

20 August 2017

volume

21

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

1-9

1 reference

Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Infection in organ-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus in transplantation - challenging the status quo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The indirect effects of cytomegalovirus infection on the outcome of organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Infections and solid organ transplant rejection: a cause-and-effect relationship?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus-associated allograft rejection in heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The natural course of cytomegalovirus infection and disease in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The Association of Cytomegalovirus Sero-Pairing with Outcomes and Costs Following Cadaveric Renal Transplantation Prior to the Introduction of Oral Ganciclovir CMV Prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Epidemiology and management of infections after lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Definitions of cytomegalovirus infection and disease in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation--early risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Late and atypical cytomegalovirus disease in solid-organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Immunologic predictors of late cytomegalovirus disease after solid organ transplantation--an elusive goal?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Late-onset cytomegalovirus reactivation in critically ill renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Clinical significance of CMV-specific T helper responses in lung transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Hypogammaglobulinemia in lung transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Life after 20 years with a kidney transplant: redefined disease profiles and an emerging nondiabetic vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Ganciclovir-resistant cytomegalovirus in organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The clinical significance of ganciclovir resistance in a renal transplant patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cellular immune responses to cytomegalovirus in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus infection following liver transplantation: review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab Induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus (CMV) resistance to antivirals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Leflunomide therapy for cytomegalovirus disease in renal allograft recepients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Delayed-onset primary cytomegalovirus disease after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.12.004

10.1016/J.TRIM.2008.12.004

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference